SecBot SecBot
PRESS-RELEASE ·Filed Nov 11, 2026

INKT

MiNK Therapeutics
NEUTRAL
Impact 4/10
Horizonmonths Processed5d 16h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor U.S. site activation and dosing in the randomized ARDS trial before year-end, and any FDA feedback on the adaptive Phase 2b/3 design. The company's cash runway ($7.5M) and operating burn rate suggest a need for additional financing within the next 2-3 quarters to fund the trial through its 2H2027 readout.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

INKT drug pipeline →

agenT-797

● Neutral Named in this press release
Impact
Phase
Phase 2
Time to market
agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
Next catalyst
None dated

What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$10.22
T+0 close · Nov 11, 2026 · via day close
Latest settled
−6.79%
T+1 · $9.53
Vs SPY
−6.43%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $10.22entry
  2. T+1 · 5d ago −6.79%α −6.43% · $9.53
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics reported Q3 2026 net loss of $2.6M ($0.50 per share), narrower than the $2.9M loss ($0.65 per share) in the prior-year quarter, and recognized its first pre-commercial product revenue of $0.2M from named-patient access of agenT-797. The company ended the quarter with $7.5M in cash, down from $8.8M at June 30, 2026, and reported the lowest quarterly operating cash use of 2026 at $1.3M. Key catalysts include the ongoing randomized Phase 2 ARDS trial with U.S. dosing expected before year-end and data expected in 2H2027, and selection for ARPA-H's BoSS program (up to $87M in program-wide funding).

Key Financial Metrics

EPS
−$0.50
Revenue
$200.0K
est $75.0K · +166.7%

Key Facts

  • Q3 2026 net loss $2.6M ($0.50 per share) vs $2.9M ($0.65) in prior-year quarter; 23% improvement in net loss per share
  • First pre-commercial product revenue of $0.2M from named-patient access of agenT-797
  • Cash and cash equivalents $7.5M at Sep 30, 2026, down from $8.8M at Jun 30, 2026
  • Cash used in operations $1.3M in Q3 2026, lowest quarterly operating cash use of 2026
  • General and administrative expense declined 44% to $1.0M
  • Research and development expense increased to $1.8M from $1.1M, driven by randomized Phase 2 ARDS trial activity
  • Randomized Phase 2 ARDS trial (C-1300-02) enrolling; U.S. dosing expected before year-end 2026; data expected 2H2027
  • agenT-797 selected for ARPA-H BoSS program (Draper-led team; up to $87M program-wide funding)
  • SITC 2026 data showed agenT-797 and MiNK-215 as 'living senolytics' in preclinical models

Financial Impact

Net loss improved 23% per share; first product revenue of $0.2M; cash burn reduced to $1.3M operating cash use in Q3

revenuenet losscash positionoperating expenses

Risk Factors

  • Cash runway limited; company may need to raise capital to fund randomized trial through readout
  • Pre-commercial revenue is variable and depends on physician requests and regulatory authorizations
  • Early clinical and preclinical data may not predict outcomes in controlled studies
  • Randomized ARDS trial results are not expected until 2H2027, creating a long catalyst timeline

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3400610

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Viewing Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 11, 2026